Company: NDRA
Filing Date: 2025-06-11
Form Type: 8-K
Source: 0001654954-25-006811
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-06-11
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure

On June 11, 2025, ENDRA Life Sciences Inc. (the “ Company”) posted to its website an investor presentation reflecting its new business strategy announced in its press release issued on March 31, 2025. The investor presentation may be found on the Company’s website at https://investors. endrainc. com.

The information in this Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ENDRA Life Sciences Inc.                               
  June 11, 2025                                          
  By:                           /s/ Richard Jacroux      
  Name:                         Richard Jacroux          
  Title:                        Chief Financial Officer  

   3